Cargando…

Seroprevalence of antibodies to herpes simplex virus 1 and 2 in patients with HIV positive from Ebonyi State, Nigeria: a cross-sectional study

OBJECTIVES: To assess the seroprevalence of herpes simplex virus (HSV) types 1 and 2 in patients infected with HIV in Nigeria. DESIGN: Cross-sectional design from January to June 2019. SETTING: Federal Teaching Hospital, Ebonyi State, Nigeria. PARTICIPANTS: A total of 276 patients with HIV were anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Onu, Euslar Nnenna, Ekuma, Uchechukwu Onyeukwu, Judi, Hawraa K, Ogbu, Ogbonnaya, Okoro, Nworie, Ajugwo, Gloria C, Akrami, Sousan, Okoli, Chukwudum S, Anyanwu, Chioma Ngozi, Saki, Morteza, Edeh, Peter Anyigor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124271/
https://www.ncbi.nlm.nih.gov/pubmed/37072358
http://dx.doi.org/10.1136/bmjopen-2022-069339
_version_ 1785029804285755392
author Onu, Euslar Nnenna
Ekuma, Uchechukwu Onyeukwu
Judi, Hawraa K
Ogbu, Ogbonnaya
Okoro, Nworie
Ajugwo, Gloria C
Akrami, Sousan
Okoli, Chukwudum S
Anyanwu, Chioma Ngozi
Saki, Morteza
Edeh, Peter Anyigor
author_facet Onu, Euslar Nnenna
Ekuma, Uchechukwu Onyeukwu
Judi, Hawraa K
Ogbu, Ogbonnaya
Okoro, Nworie
Ajugwo, Gloria C
Akrami, Sousan
Okoli, Chukwudum S
Anyanwu, Chioma Ngozi
Saki, Morteza
Edeh, Peter Anyigor
author_sort Onu, Euslar Nnenna
collection PubMed
description OBJECTIVES: To assess the seroprevalence of herpes simplex virus (HSV) types 1 and 2 in patients infected with HIV in Nigeria. DESIGN: Cross-sectional design from January to June 2019. SETTING: Federal Teaching Hospital, Ebonyi State, Nigeria. PARTICIPANTS: A total of 276 patients with HIV were analysed using ELISA method for the presence of HSV-1 and HSV-2 specific IgG antibodies. OUTCOMES: Fisher’s exact test was used to determine the association between the seroprevalence of HSV and demographic variables (statistically significant=p value ≤0.05). RESULTS: Totally, 212 (76.8%) and 155 (56.2%) patients with HIV were seropositive for HSV-1 and HSV-2 IgG antibodies, respectively. The seroprevalence of HSV-1 was significantly higher than the HSV-2 in patients with HIV (p value <0.0001). HSV-1 and HSV-2 seroprevalence were higher in patients aged more than 30 years. The seroprevalence of HSV-1 was significantly higher (p=0.01) in females (82.4%, 131/159) than males (69.2%, 81/117), but there was no significant difference in seroprevalence of HSV-2 in females (57.9%, 92/159) compared with males (53.8%, 63/117) (p=0.51). Professional drivers had a higher seroprevalence of HSV-1 and HSV-2 and there was a significant association between the occupation and the HSV-1 and HSV-2 seropositivity (p>0.05). The seroprevalence of HSV-1 was significantly higher in the singles (87.4%, 90/103) than the married patients with HIV (p=0.001). However, HSV-2 seroprevalence was significantly higher in the married patients with HIV (63.6%, 110/173) (p=0.001). CONCLUSIONS: Prevalence of 76.8% for HSV-1 and 56.2% for HSV-2 among patients with HIV was seen. The HSV-1 was significantly higher in the singles while HSV-2 seroprevalence was significantly higher in the married patients with HIV with HSV-1 and HSV-2 coinfection rate of 7.6%. This study became very imperative to provide an important insight into the hidden dynamics of HSV infections.
format Online
Article
Text
id pubmed-10124271
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-101242712023-04-25 Seroprevalence of antibodies to herpes simplex virus 1 and 2 in patients with HIV positive from Ebonyi State, Nigeria: a cross-sectional study Onu, Euslar Nnenna Ekuma, Uchechukwu Onyeukwu Judi, Hawraa K Ogbu, Ogbonnaya Okoro, Nworie Ajugwo, Gloria C Akrami, Sousan Okoli, Chukwudum S Anyanwu, Chioma Ngozi Saki, Morteza Edeh, Peter Anyigor BMJ Open HIV/AIDS OBJECTIVES: To assess the seroprevalence of herpes simplex virus (HSV) types 1 and 2 in patients infected with HIV in Nigeria. DESIGN: Cross-sectional design from January to June 2019. SETTING: Federal Teaching Hospital, Ebonyi State, Nigeria. PARTICIPANTS: A total of 276 patients with HIV were analysed using ELISA method for the presence of HSV-1 and HSV-2 specific IgG antibodies. OUTCOMES: Fisher’s exact test was used to determine the association between the seroprevalence of HSV and demographic variables (statistically significant=p value ≤0.05). RESULTS: Totally, 212 (76.8%) and 155 (56.2%) patients with HIV were seropositive for HSV-1 and HSV-2 IgG antibodies, respectively. The seroprevalence of HSV-1 was significantly higher than the HSV-2 in patients with HIV (p value <0.0001). HSV-1 and HSV-2 seroprevalence were higher in patients aged more than 30 years. The seroprevalence of HSV-1 was significantly higher (p=0.01) in females (82.4%, 131/159) than males (69.2%, 81/117), but there was no significant difference in seroprevalence of HSV-2 in females (57.9%, 92/159) compared with males (53.8%, 63/117) (p=0.51). Professional drivers had a higher seroprevalence of HSV-1 and HSV-2 and there was a significant association between the occupation and the HSV-1 and HSV-2 seropositivity (p>0.05). The seroprevalence of HSV-1 was significantly higher in the singles (87.4%, 90/103) than the married patients with HIV (p=0.001). However, HSV-2 seroprevalence was significantly higher in the married patients with HIV (63.6%, 110/173) (p=0.001). CONCLUSIONS: Prevalence of 76.8% for HSV-1 and 56.2% for HSV-2 among patients with HIV was seen. The HSV-1 was significantly higher in the singles while HSV-2 seroprevalence was significantly higher in the married patients with HIV with HSV-1 and HSV-2 coinfection rate of 7.6%. This study became very imperative to provide an important insight into the hidden dynamics of HSV infections. BMJ Publishing Group 2023-04-18 /pmc/articles/PMC10124271/ /pubmed/37072358 http://dx.doi.org/10.1136/bmjopen-2022-069339 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle HIV/AIDS
Onu, Euslar Nnenna
Ekuma, Uchechukwu Onyeukwu
Judi, Hawraa K
Ogbu, Ogbonnaya
Okoro, Nworie
Ajugwo, Gloria C
Akrami, Sousan
Okoli, Chukwudum S
Anyanwu, Chioma Ngozi
Saki, Morteza
Edeh, Peter Anyigor
Seroprevalence of antibodies to herpes simplex virus 1 and 2 in patients with HIV positive from Ebonyi State, Nigeria: a cross-sectional study
title Seroprevalence of antibodies to herpes simplex virus 1 and 2 in patients with HIV positive from Ebonyi State, Nigeria: a cross-sectional study
title_full Seroprevalence of antibodies to herpes simplex virus 1 and 2 in patients with HIV positive from Ebonyi State, Nigeria: a cross-sectional study
title_fullStr Seroprevalence of antibodies to herpes simplex virus 1 and 2 in patients with HIV positive from Ebonyi State, Nigeria: a cross-sectional study
title_full_unstemmed Seroprevalence of antibodies to herpes simplex virus 1 and 2 in patients with HIV positive from Ebonyi State, Nigeria: a cross-sectional study
title_short Seroprevalence of antibodies to herpes simplex virus 1 and 2 in patients with HIV positive from Ebonyi State, Nigeria: a cross-sectional study
title_sort seroprevalence of antibodies to herpes simplex virus 1 and 2 in patients with hiv positive from ebonyi state, nigeria: a cross-sectional study
topic HIV/AIDS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124271/
https://www.ncbi.nlm.nih.gov/pubmed/37072358
http://dx.doi.org/10.1136/bmjopen-2022-069339
work_keys_str_mv AT onueuslarnnenna seroprevalenceofantibodiestoherpessimplexvirus1and2inpatientswithhivpositivefromebonyistatenigeriaacrosssectionalstudy
AT ekumauchechukwuonyeukwu seroprevalenceofantibodiestoherpessimplexvirus1and2inpatientswithhivpositivefromebonyistatenigeriaacrosssectionalstudy
AT judihawraak seroprevalenceofantibodiestoherpessimplexvirus1and2inpatientswithhivpositivefromebonyistatenigeriaacrosssectionalstudy
AT ogbuogbonnaya seroprevalenceofantibodiestoherpessimplexvirus1and2inpatientswithhivpositivefromebonyistatenigeriaacrosssectionalstudy
AT okoronworie seroprevalenceofantibodiestoherpessimplexvirus1and2inpatientswithhivpositivefromebonyistatenigeriaacrosssectionalstudy
AT ajugwogloriac seroprevalenceofantibodiestoherpessimplexvirus1and2inpatientswithhivpositivefromebonyistatenigeriaacrosssectionalstudy
AT akramisousan seroprevalenceofantibodiestoherpessimplexvirus1and2inpatientswithhivpositivefromebonyistatenigeriaacrosssectionalstudy
AT okolichukwudums seroprevalenceofantibodiestoherpessimplexvirus1and2inpatientswithhivpositivefromebonyistatenigeriaacrosssectionalstudy
AT anyanwuchiomangozi seroprevalenceofantibodiestoherpessimplexvirus1and2inpatientswithhivpositivefromebonyistatenigeriaacrosssectionalstudy
AT sakimorteza seroprevalenceofantibodiestoherpessimplexvirus1and2inpatientswithhivpositivefromebonyistatenigeriaacrosssectionalstudy
AT edehpeteranyigor seroprevalenceofantibodiestoherpessimplexvirus1and2inpatientswithhivpositivefromebonyistatenigeriaacrosssectionalstudy